Trial Profile
Efficacy and Safety of Oral Octreolin in Patients With Acromegaly Who Are Currently Receiving Parenteral Somatostatin Analogs
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Octreotide (Primary)
- Indications Acromegaly
- Focus Registrational; Therapeutic Use
- Sponsors Chiasma
- 31 Aug 2015 According to a Chiasma media release, the agency has set a target review date under the Prescription Drug User Fee Act (PDUFA) of April 15, 2016.
- 17 Aug 2015 According to a Chiasma media release, the U.S. FDA has accepted for filing the company's NDA for octreotide capsules for the maintenance therapy of adult patients with acromegaly.
- 16 Jun 2015 According to a Chiasma media release, the company has submitted a New Drug Application for the Octreotide capsules to the US FDA as the maintenance treatment of adults with acromegaly, based on the results of this trial in June 2015.